<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested initial antimicrobial therapy for high-risk* children with fever and chemotherapy-induced neutropenia&lt;sup&gt;[1,2]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested initial antimicrobial therapy for high-risk* children with fever and chemotherapy-induced neutropenia<sup>[1,2]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested initial antimicrobial therapy for high-risk* children with fever and chemotherapy-induced neutropenia<sup>[1,2]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="divider_bottom" colspan="2"><span class="red">Fever and neutropenia in children with cancer or HCT is a medical emergency. Empiric-broad spectrum antibiotics should be given as soon as possible: within 60 minutes of triage and immediately after blood cultures have been obtained.</span></td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="2">Suggested agents for broad-spectrum empiric IV therapy (1 of the following<sup>¶</sup>):</td> </tr> <tr class="divider_bottom"> <td class="indent1" colspan="2"> <ul> <li>Cefepime</li> <li>Meropenem</li> <li>Piperacillin-tazobactam</li> </ul> </td> </tr> <tr class="divider_bottom divider_top"> <td class="subtitle1_left">Selected limited indications for additional agents</td> <td class="subtitle1_left">Suggested additional agent(s)</td> </tr> <tr class="divider_bottom"> <td colspan="2">Additional gram-positive (eg, vancomycin, clindamycin, linezolid) and/or gram-negative (eg, aminoglycosides) agents should be discontinued after 48 hours in children with no documented infection who remain clinically stable.</td> </tr> <tr class="divider_bottom"> <td class="indent1">Signs of sepsis (eg, fever, hypotension, unexplained tachycardia and/or widened pulse pressure, mental status change, respiratory dysfunction)</td> <td class="indent1">Add agents with activity against gram-negative bacteria (eg, aminoglycoside, fluroquinolone) and MRSA (eg, vancomycin) after consultation with an expert in pediatric infectious diseases and an expert in critical care</td> </tr> <tr class="divider_bottom"> <td class="indent1">Abdominal pain, rectal pain, perineal inflammation, or blood per rectum</td> <td class="indent1">Add metronidazole if not already receiving antibiotics active against anaerobes (eg, meropenem, piperacillin-tazobactam)</td> </tr> <tr class="divider_bottom"> <td class="indent1">Suspected <em>Clostridioides difficile</em> infection</td> <td class="indent1"> <ul> <li>Nonsevere initial episode: Add metronidazole or oral vancomycin</li> <li>Severe initial episode: Add oral vancomycin</li> <li>Recurrent episode: Add oral vancomycin or oral fidaxomicin</li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2">Positive blood culture (before identification)</td> </tr> <tr> <td class="indent2"> <ul> <li>Gram-negative</li> </ul> </td> <td class="indent1">Add an aminoglycoside and change the initial agent to a carbapenem (eg, meropenem) if a carbapenem was not chosen initially</td> </tr> <tr class="divider_bottom"> <td class="indent2"> <ul> <li>Gram-positive</li> </ul> </td> <td class="indent1">Add 1 of the following: <ul class="decimal_heading"> <li>Vancomycin</li> <li>Linezolid</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Meningitis or suspected meningitis</td> <td class="indent1">Add vancomycin to antipseudomonal therapy with cefepime or meropenem<sup>Δ</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">Radiographically documented pneumonia</td> <td class="indent1">Add vancomycin if MRSA suspected</td> </tr> <tr class="divider_bottom"> <td class="indent1">Clinically suspected CVC infection</td> <td class="indent1">Add vancomycin<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">Skin or soft tissue infection</td> <td class="indent1">Add 1 of the following: <ul class="decimal_heading"> <li>Vancomycin</li> <li>Clindamycin</li> <li>Linezolid</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Known colonization with MRSA or penicillin- and cephalosporin-resistant <em>Streptococcus pneumoniae</em></td> <td class="indent1">Add 1 of the following: <ul class="decimal_heading"> <li>Vancomycin</li> <li>Clindamycin</li> <li>Linezolid</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Recent intensive chemotherapy associated with a high risk for infection with penicillin-resistant streptococci (eg, high-dose cytarabine)</td> <td class="indent1">Add 1 of the following: <ul class="decimal_heading"> <li>Vancomycin</li> <li>Clindamycin</li> <li>Linezolid</li> </ul> </td> </tr> <tr> <td class="indent1">Prophylaxis with quinolones during afebrile neutropenia</td> <td class="indent1">Add 1 of the following: <ul class="decimal_heading"> <li>Vancomycin</li> <li>Clindamycin</li> <li>Linezolid</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is intended for use with UpToDate content related to fever in children with fever and chemotherapy-induced neutropenia. Refer to UpToDate content for additional details (eg, risk stratification, doses, duration, modification of empiric therapy). The initial empiric regimen is individualized (eg, for drug allergies, organ dysfunction, use of prophylactic antimicrobial agents).

<ul class="decimal_heading">
<li>The combination of vancomycin and piperacillin-tazobactam is associated with increased risk of acute kidney injury and should be avoided.</li>
<li>Linezolid should be reserved for children known to be colonized with or previously infected with vancomycin-resistant gram-positive organisms.</li>
<li>Clindamycin should be chosen only if the rates of clindamycin resistance in the cancer center and community are acceptably low.</li>
</ul></div><div class="graphic_footnotes">HCT: hematopoietic cell transplant; IV: intravenous; MRSA: methicillin-resistant <em>Staphylococcus aureus</em>; CVC: central venous catheter.<br/>* Children are assessed to be at high risk of severe infection or complications at the onset of their episode of fever and neutropenia. They may be reassigned from low to high risk if the develop 1 or more of the high-risk criteria.<br/>¶ For high-risk children following HCT, cefepime is preferred to meropenem and piperacillin-tazobactam.<br/>Δ If meropenem is used as the broad-spectrum antipseudomonal agent, use the dose for central nervous system infections: 40 mg/kg IV every 8 hours (maximum of 2 g per dose).<br/><span class="lozenge">◊</span> Alternatives to vancomycin include ceftaroline or daptomycin, although these agents are not used routinely.</div><div class="graphic_reference">References:

<ol>
<li>Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:e56.</li>
<li>Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol 2017; 35:2082.</li>
</ol></div><div id="graphicVersion">Graphic 120756 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
